Functions of Human Papillomavirus Proteins

  • M. Scheffner
  • H. Romanczuk
  • K. Münger
  • J. M. Huibregtse
  • J. A. Mietz
  • P. M. Howley
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 186)

Abstract

Cervical cancer is the second leading cause of deaths from cancer among women worldwide with approximately 500 000 deaths annually. Epidemiologic studies have implicated a sexually transmitted agent as a cause of cervical cancer, and molecular virology studies over the past 10 years have established a strong association between specific human papillomavirus (HPV) types and certain anogenital carcinomas, including cervical cancer (reviewed in zur Hausen and Schneider 1987). Over 65 different HPV types have now been described, and each is associated with a specific clinical entity (DeVilliers 1989). Approximately 20 or 25 HPVs have been associated with anogenital lesions; these HPVs have been further classified as either “low-risk” or “high-risk” types based on the preneoplastic character of the clinical lesions with which they are associated. Low-risk HPVs such as HPV-6 and HPV-11 are generally associated with venereal warts or condyloma acuminata which only rarely progress to malignancy. The high-risk HPVs include HPV-16 and HPV-18 and these are associated with squamous intraepithelial neoplasias which are potentially precancerous. In the cervix, they are associated with cervical intraepithelial neoplasia, or CIN. These CIN lesions are considered preneoplastic in that a small percentage of high-grade CIN lesions will progress to cervical cancer. Approximately 70% of human cervical cancers contain either HPV-16 or HPV-18 DNA (zur Hausen and Schneider 1987). Indeed, HPV-16 and HPV-18 DNA were originally isolated from human cervical carcinoma tissues (Dürst et al. 1983; Boshart et al. 1984). Other high-risk HPVs, including types 31, 33, 35, 39, 45, 51, and 52, have subsequently been identified and have also been associated with CIN lesions and with invasive cervical carcinomas. All together, approximately 85% of cervical cancers can be shown to contain DNA of one of the high-risk HPV types (Riou et al. 1990).

Keywords

Zinc Glycine Serine Polypeptide Half Life 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Androphy EJ, Lowy DR, Schiller JT (1987) Bovine papillomavirus E2 transactivating gene product binds to specific sites in papillomavirus DNA. Nature 325:70–73.PubMedCrossRefGoogle Scholar
  2. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM (1987) Structural and translational analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 61:962–971.PubMedGoogle Scholar
  3. Band V, DeCaprio JA, Delmolino L, Kulesa V, Sager R (1991) Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J Virol 65:6671–6676.PubMedGoogle Scholar
  4. Barbosa MS, Lowy DR, Schiller JT (1989) Papillomavirus polypeptides E6 and E7 are zincbinding proteins. J Virol 63:1404–1407.PubMedGoogle Scholar
  5. Bernard BA, Bailly C, Lenoir M-C, Darmon M, Thierry F, Yaniv M (1989) The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the H PV18 regulatory region in human keratinocytes. J Virol 63:4317–4324.PubMedGoogle Scholar
  6. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Schleurlen W, zur Hausen H (1984) A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 3:1151–1157.PubMedGoogle Scholar
  7. Chellappan S, Kraus VB, Kroger B, Münger K, Howley PM, Phelps WC, Nevins JR (1992) Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between the transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 89:4549–4553.PubMedCrossRefGoogle Scholar
  8. Chiang C-M, Ustav M, Stenlund A, Ho TF, Broker TR, Chow LT (1992) Viral E1 and E2 proteins support replication of homologous and heterologous papillomavirus origins. Proc Natl Acad Sci USA 89:5799–5803.PubMedCrossRefGoogle Scholar
  9. Chow LT, Nasseri M, Wolinsky SM, Broker TM (1987) Human papillomavirus types 6 and 11 mRNAs from genital condylomata acuminata. J Virol 61:2581–2588.PubMedGoogle Scholar
  10. Clertant P, Seif I (1984) A common function for polyoma virus large-T and papillomavirus E1 proteins. Nature 311:276–279.PubMedCrossRefGoogle Scholar
  11. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA (1992) The retinoblastoma protein and the regulation of cell cycling. TIBS 17:312–315.PubMedGoogle Scholar
  12. Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid PG, Durst M, Gissmann L, Roman A, Turek LP (1987) Transcriptional regulation of the human papillomavirus-16 E6–E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene products: implications for cervical carcinogenesis. EMBO J 6:3745–3753.PubMedGoogle Scholar
  13. Crook T, Tidy JA, Vousden KH (1991) Degradation of p53 can be targeted by H PV E6 sequences distinct from those required for p53 building and transactivation. Cell 67:547–556.PubMedCrossRefGoogle Scholar
  14. DeCaprio JA, Ludlow JW, Figge J, Shew J-Y, Huang C-M, Lee W-H, Marsilio EEP, Livingston DM (1988) SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275–283.PubMedCrossRefGoogle Scholar
  15. Del Vecchio AM, Romanczuk H, Howley PM, Baker CC (1992) Transient replication of human papillomavirus DNAs. J Virol 66:5949–5958.PubMedGoogle Scholar
  16. DeVilliers, EM (1989) Heterogeneity of the human papillomavirus group. J Virol 63:4898–4903.Google Scholar
  17. Dürst M, Gissmann L, Idenburg H, Zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80:3812–3815.PubMedCrossRefGoogle Scholar
  18. Dürst M, Kleinheinz A, Hotz M, Gissmann L (1985) The physical state of human papillomavirus type 16 in benign and malignant genital tumors. J Gen Virol 66:1515–1522.PubMedCrossRefGoogle Scholar
  19. Dürst M, Croce CM, Gissmann L, Schwarz E, Huebner K (1987) Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci USA 80:3812–3815.CrossRefGoogle Scholar
  20. Dyson N, Howley PM, Münger K, Harlow E (1989) The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934–937.PubMedCrossRefGoogle Scholar
  21. Dyson N, Guida P, Münger K, Harlow E (1992) Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 66:6893–6902.PubMedGoogle Scholar
  22. Edmonds C, Vousden KH (1989) A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol 63:2650–2656.PubMedGoogle Scholar
  23. Ewen M, Xing Y, Lawrence JB, Livingston DM (1991) Molecular cloning, chromosomal mapping, and expression of p107, a retinoblastoma gene product related protein. Cell 66:1155–1164.PubMedCrossRefGoogle Scholar
  24. Funk WD, Pak DT, Karas RH, Wright WE, Shay, JW (1992) A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866–2871.PubMedGoogle Scholar
  25. Grossman SR, Laimins LA (1989) E6 protein of human papillomavirus type 18 binds zinc. Oncogene 4:1089–1093.PubMedGoogle Scholar
  26. Grossman SR, Mora R, Laimins LA (1989) Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector. J Virol 63:366–374.PubMedGoogle Scholar
  27. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT (1989) HPV; 6 Et and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905–3910.PubMedGoogle Scholar
  28. Heck DV, Yee CL, Howley PM, Münger K (1992) Efficiency of binding to the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 89:4442–4446.PubMedCrossRefGoogle Scholar
  29. Hedge RS, Rossman SR, Laimins LA, Sigler PB (1992) Crystal structure at 1.7A of the bovine papillomavirus-1 E2 DNA-binding domain bound to its DNA target. Nature 359:505–512.CrossRefGoogle Scholar
  30. Huang PS, Patrick DR, Edwards G, Goodhart PJ, Huber HE, Miles L, Garsky VM, Oliff A, Heimbrook DC (1993) Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol Cell Biol 13:953–960.PubMedGoogle Scholar
  31. Hubbert NL, Sedman SA, Schiller JT (1992) Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 66:6237–6241.PubMedGoogle Scholar
  32. Hudson JB, Bedell MA, McCance DJ, Laimins LA (1990) Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 64:519–526.PubMedGoogle Scholar
  33. Huibregtse JM, Scheffner M, Howley PM (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10:4129–4135.PubMedGoogle Scholar
  34. Huibregtse JM, Scheffner M, Howley PM (1993) Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 13:775–784.PubMedGoogle Scholar
  35. Jewers RJ, Hildebrandt P, Ludlow JW, Kell B, McCance DJ (1992) Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J Virol 66:1329–1335.PubMedGoogle Scholar
  36. Karlen S, Beard P (1993) Identification and characterization of novel promoters in the genome of human papillomavirus type 18. J Virol 67:4296–4306.PubMedGoogle Scholar
  37. Kastan MB, Zhan Q, El Deiry W-S, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace A-J Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD 45 is defective in ataxia-telangiectasia. Cell 71:587–597.PubMedCrossRefGoogle Scholar
  38. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827–830.PubMedCrossRefGoogle Scholar
  39. Kessis TD, Slebos RJ, Nelson WG, Kasta MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR (1993) Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 90:3988–3992.PubMedCrossRefGoogle Scholar
  40. Lambert PF (1991) Papillomavirus DNA replication. J Virol 65:3417–3420.PubMedGoogle Scholar
  41. Lambert PF, Howley PM (1988) Bovine papillomavirus type 1 E1 replication-defective mutants are altered in their transcriptional regulation. J Virol 62:4009–4015.PubMedGoogle Scholar
  42. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH, Laimins LA (1992) Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J 11:3045–3052.PubMedGoogle Scholar
  43. Li R, Knight J, Bream G, Stenlund A, Botchan M (1989) Specific recognition nucleotides and their DNA context determine the affinity of E2 protein for 17 binding sites in the BPV-1 genome. Genes Dev 3:510–526.PubMedCrossRefGoogle Scholar
  44. Matlashewski G, Schneider J, Banks L, Jones N, Murray A, Crawford L (1987) Human papillomavirus type 16 DNA co-operates with activated ras in transforming primary cells. EMBO J 6:1141–1146.Google Scholar
  45. McBride AA, Romanczuk H, Howley PM (1991) the papillomavirus E2 regulatory proteins. J Biol chem 266:18411–18414.PubMedGoogle Scholar
  46. Mietz JA, Unger T, Huibregtse JM, Howley PM (1992) The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11:5013–5020.PubMedGoogle Scholar
  47. Mohr IJ, Clark R, Sun S, Androphy EJ, ManPherson P, Botchan MR (1990) Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. Science 250:1694–1699.PubMedCrossRefGoogle Scholar
  48. Münger K, Phelps WC, Bubb V, Howley PM, Schlegel R (1989a) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417–4421.PubMedGoogle Scholar
  49. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM (1989b) Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8:4099–4105.PubMedGoogle Scholar
  50. Münger K, Scheffner M, Huibregtse JM, Howley PM (1992) Interactions of HPV E6 and E7 with tumor suppressor gene products. Cancer Surv 12:197–217.PubMedGoogle Scholar
  51. Nevins JR (1992) A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424–429.PubMedCrossRefGoogle Scholar
  52. Oren M, Maltzman W, Levine AJ (1981) Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1:101–110.PubMedGoogle Scholar
  53. Pagano M, Dürst M, Joswig S, Draetta G, Jansen-Dürr P (1992) Binding of the human E2F transcription factor to the retinoblastoma protein but not to cyclin A is abolished in HPV-16-immortalized cells. Oncogene 7:1681–1686.PubMedGoogle Scholar
  54. Phelps WC, Yee CL, Münger K, Howley PM (1988) The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to adenovirus Ela. Cell 53:539–547.PubMedCrossRefGoogle Scholar
  55. Phelps WC, Münger K, Yee CL, Barnes JA, Howley PM (1992) Structure-function analysis of the human papillomavirus E7 oncoprotein. J. Virol 66:2418–2427.PubMedGoogle Scholar
  56. Reich NC, Oren M, Levine AJ (1983) Two distinct mechanisms regulate the levels of a cellular tumor antigen. Mol Cell Biol 3:2134–2150.Google Scholar
  57. Riou G, Favre M, Jeannel D, Bourhis J, Le Doussal V, Orth G (1990) Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 335:1171–1174.PubMedCrossRefGoogle Scholar
  58. Romanczuk H, Howley PM (1992) Disruption of either the E1 or E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci USA 89:3159–3163.PubMedCrossRefGoogle Scholar
  59. Romanczuk H, Thierry F, Howley PM (1990) Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 p97 and type 18 p105 promoters. J Virol 64:2849–2859.PubMedGoogle Scholar
  60. Sandler AB, Vande Pol SB, Spalholz BS (1993) Repression of BPV-1 transcription by the E1 replication protein. J Virol 67: (in press).Google Scholar
  61. Sand B-C, Barbosa MS (1992) Single amino acid substitutions in “low risk” human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the “high risk” HPV E7 oncoproteins. Proc Natl Acad Sci USA 89:8063–8067.CrossRefGoogle Scholar
  62. Sato H, Furuno A, Yoshiike K (1989) Expression of human papillomavirus type 16 E7 gene induces DNA synthesis of rat 3Y1 cells. Virology 168:195–199.PubMedCrossRefGoogle Scholar
  63. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136.PubMedCrossRefGoogle Scholar
  64. Scheffner M, Münger K, Byrne JC, Howley PM (1991) the state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 88:5523–5527.PubMedCrossRefGoogle Scholar
  65. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6-AP complex functions as a ubiquitin-protein ligase in the ubiquination of p53. Cell 75 (in press).Google Scholar
  66. Schiller JT, Kleiner E, Androphy EJ, Lowy DR, Pfister H (1989) Identification of bovine papillomavirus E1 mutants with increased transforming and transcriptional activity. J Virol 63:1775–1782.PubMedGoogle Scholar
  67. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen H (1985) Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314:111–114.PubMedCrossRefGoogle Scholar
  68. Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Hass JA, Lowy DR, Schiller JT (1991) The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J Virol 65:4860–4866.PubMedGoogle Scholar
  69. Seo Y-S, Müller F, Lusky M, Hurwitz J (1993) Bovine papilloma virus (BPV)-encoded E1 protein contains multiple activities required for BPV DNA replication. Proc Natl Acad Sci USA 90:702–706.PubMedCrossRefGoogle Scholar
  70. Smotkin D, Wettstein F0 (1986) Transcription of human papillomavirus type 16 early genes in cervical cancer and a cervical cancer derived cell line and identification of the E7 protein. Proc Natl Acad Sci USA 83:4680–4684.PubMedCrossRefGoogle Scholar
  71. Stirdivant SM, Huber HE, Patrick DR, Defeo-Jones D, McAvoy EM, Garsky VM, Oliff A, Heimbrook DC (1992) Human papillomavirus type 16 E7 protein inhibits DNA binding by the retinoblastoma gene product. Mol Cell Biol 12:1905–1914.PubMedGoogle Scholar
  72. Swift FV, Bhat K, Younghusband HB, Hamada H (1987) Characterization of a cell type-specific enhancer found in the human papilloma virus type 18 genome. EMBO J 6:1339–1344.PubMedGoogle Scholar
  73. Thierry F, Howley PM (1991) Functional analysis of E2-mediated repression of the HPV18 P105 promoter. New Biol 3:90–100.PubMedGoogle Scholar
  74. Thierry F, Yaniv M (1987) The BPV-1 E trans-acting protein can be either an activator or repressor of the HPV-18 regulatory region. EMBO J 6:3391–3397.PubMedGoogle Scholar
  75. Tommasino M, Adamczewski JP, Carlotti F, Barth CF, Manetti R, Contorni M, Cavalieri F, Hunt T, Crawford L (1993) HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 8:195–202.PubMedGoogle Scholar
  76. Ustav M, Stenlund A (1991) Transient replication of BPV-1 requires two viral polypeptides encoded by E1 and E2 open reading frames. EMBO J 10:449–457.PubMedGoogle Scholar
  77. Ustav M, Ustav E, Szymanski P, Stenlund, A (1991) Identification of the origin of replication of bovine papillomavirus and characterization of the viral origin recognition factor E1. EMBO J 10:4321–4329.PubMedGoogle Scholar
  78. von Knebel-Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L (1988) Correlation to modify human papillomavirus early gene expression with altered growth properties in C4-I cervical carcinoma cells. Cancer Res 48:3780–3785.Google Scholar
  79. Werness BA, Levine AJ, Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76–79.PubMedCrossRefGoogle Scholar
  80. Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, Weinberg RA, Harlow E (1988) Association between an oncogene and an antioncogene: the adenovirus E1 a proteins bind to the retinoblastoma gene product. Nature 334:124–129.PubMedCrossRefGoogle Scholar
  81. Whyte P, Williamson NM, Harlow E (1989) Cellular targets for transformation by the adenovirus E1A proteins. Cell 56:67–75.PubMedCrossRefGoogle Scholar
  82. Wilson VG, Ludes-Meyers J (1991) A bovine papillomavirus E1-related protein binds specifically to bovine papillmavirus DNA. J Virol 65:5314–5322.PubMedGoogle Scholar
  83. Wu EW, Clemens KE, Heck DV, Münger K (1993) The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J Virol 67:2402–2407.PubMedGoogle Scholar
  84. Yang L, Li R, Mohr IJ, Clark R, Botchan MR (1991) Activation of BPV-1 replication in vitro by the transcription factor E2. Nature 353:628–632.PubMedCrossRefGoogle Scholar
  85. Yew PR, Berk A (1992) Inhibition of p53 transactivation required for transformation by adenovirus early 1 B protein. Nature 357:82–85.PubMedCrossRefGoogle Scholar
  86. zur Hausen H (1991) Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9–13.PubMedCrossRefGoogle Scholar
  87. zur Hausen H, Schneider A (1987) The role of papilloma-viruses in human anogenital cancers. In: Salzman N, Howley PM (eds) The papoviridae, vol 2: the papillomaviruses. Plenum, New York, pp 245–263.Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1994

Authors and Affiliations

  • M. Scheffner
    • 1
  • H. Romanczuk
    • 1
  • K. Münger
    • 1
  • J. M. Huibregtse
    • 1
  • J. A. Mietz
    • 1
  • P. M. Howley
    • 1
  1. 1.Laboratory of Tumor Virus BiologyNational Cancer InstituteBethesdaUSA

Personalised recommendations